FDA Spinal Disc Draft Guidance Under Development; AAOS Weighs In
This article was originally published in The Gray Sheet
FDA's planned draft guidance on preclinical and clinical trial design for spinal disc replacement systems might draw on a FDL-1proposed guidance developed by the American Association of Orthopaedic Surgeons
You may also be interested in...
Johnson & Johnson/DePuy Spine should collect two years of postmarket follow-up data on Charité artificial lumbar disc recipients, according to FDA's Orthopaedic & Rehabilitation Devices Panel
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.